MacroGenics, Inc. (MGNX) Rating Lowered to Strong Sell at ValuEngine

ValuEngine cut shares of MacroGenics, Inc. (NASDAQ:MGNX) from a sell rating to a strong sell rating in a research report sent to investors on Tuesday morning.

A number of other analysts also recently commented on MGNX. BidaskClub downgraded shares of MacroGenics from a sell rating to a strong sell rating in a report on Saturday, August 12th. Citigroup Inc. boosted their price objective on shares of MacroGenics from $18.00 to $22.00 and gave the stock a neutral rating in a report on Friday, November 10th. Morgan Stanley decreased their price objective on shares of MacroGenics from $22.00 to $21.00 and set an equal weight rating on the stock in a report on Monday, August 7th. Cowen and Company reissued a buy rating on shares of MacroGenics in a report on Friday, August 4th. Finally, Zacks Investment Research raised shares of MacroGenics from a sell rating to a hold rating in a report on Tuesday, October 10th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. MacroGenics has a consensus rating of Buy and an average price target of $30.10.

Shares of MacroGenics (MGNX) opened at $19.20 on Tuesday. MacroGenics has a fifty-two week low of $14.36 and a fifty-two week high of $29.45.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm’s quarterly revenue was down 48.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.97) EPS. analysts expect that MacroGenics will post -0.7 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “MacroGenics, Inc. (MGNX) Rating Lowered to Strong Sell at ValuEngine” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/macrogenics-inc-mgnx-rating-lowered-to-strong-sell-at-valuengine/1782553.html.

In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of MacroGenics stock in a transaction dated Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the transaction, the senior vice president now owns 40,000 shares in the company, valued at $800,000. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc raised its position in MacroGenics by 4.3% during the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 328 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of MacroGenics by 1.0% in the first quarter. Ameriprise Financial Inc. now owns 49,059 shares of the biopharmaceutical company’s stock valued at $912,000 after buying an additional 485 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of MacroGenics by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 26,485 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 743 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in shares of MacroGenics by 3.8% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,238 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 848 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of MacroGenics by 0.6% in the second quarter. Jennison Associates LLC now owns 189,970 shares of the biopharmaceutical company’s stock valued at $3,326,000 after buying an additional 1,062 shares during the last quarter. Institutional investors own 84.72% of the company’s stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.